Amid COVID-19, Quality Management matters more than ever for cell and gene therapy. Use this white paper to build on essential Quality and risk-management principles, including important information on critical risks, vendor management, and Quality metrics specific to advanced therapies.
Get the foundation your team needs with QMS principles to de-risk the complex advanced therapy supply chain.
- Reduce supply chain risk
- Enable identification of the critical supply chain risks, and identify where to deploy limited resources for the biggest benefit
- Deploy partner management and metrics resources to provide actionable information that can be implemented immediately